Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Aromasin's Impact on Bone Metabolism is Temporary: Pfizer
June 13, 2005
- IIC Encourages Japanese Investment in Eastern Germany
June 13, 2005
- Progress in 3-Year Program to Revitalize Clinical Trials Discussed
June 13, 2005
- BUSINESS NEWS IN BRIEF
June 13, 2005
- REGULATORY NEWS IN BRIEF
June 13, 2005
- JPMA to Compile Proposals for NHI Price Reform in July
June 13, 2005
- OPIR Report Presents Specific Proposals to Improve Review System
June 13, 2005
- Market for Ethical Drugs Grew 3.5% to \7,345,657 Mil. in FY2004: IMS Japan
June 13, 2005
- LDP to Call For Enhancement of Int'l Competitiveness of Pharma Industry
June 13, 2005
- Novartis to Acquire Hexal AG
June 13, 2005
- Committee Recommends Import Approval for Kissei's Salagen
June 13, 2005
- Pfizer Qualitatively and Quantitatively Beefs Up Its Marketing
June 13, 2005
- Council Listens to Industry's Views on How to Strengthen Domestic Industry's Int'l Competitiveness
June 13, 2005
- FY2005 to Be "Milepost" for Teijin Pharm: Mr Ohyagi
June 13, 2005
- PMDA's Activities in FY2004 Wrapped Up
June 13, 2005
- NEW PRODUCTS
June 6, 2005
- Teikoku Hormone: Profits Up Despite Slight Dip in Sales
June 6, 2005
- REGULATORY NEWS IN BRIEF
June 6, 2005
- Yakult Honsha: Pharma Div. Sees 2.1% Decline in Sales
June 6, 2005
- Kobayashi: Sales Up 1.9% at \215,708 Mil.
June 6, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…